Q-omics provides the consensus-scored LCT profile across patient tissues and cancer cell-line models. LCT expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, LCT is differentially expressed in 10, with the highest sampling consensus in BLCA. Additionally, LCT RNA expression shows 11,779 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, BLCA, and GBM as cancer lineages where LCT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LCT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LCT survival associations across molecular data types. LCT RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LCT RNA expression–survival associations across cancer types. High LCT expression shows unfavorable associations in LIHC, ACC and LGG, but favorable associations in HNSC, BLCA and CESC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for LCT RNA expression.
This table summarizes LCT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for LCT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LCT shows lower tumor expression in STAD and higher tumor expression in BLCA, LUAD, LIHC, UCEC and LUSC. The BLCA box plot shows higher LCT RNA expression in tumor versus normal tissue (log2 FC = +0.035, t-test p = .019).
This table shows molecular features associated with LCT in patient tissues and cancer cell lines. In patient samples, LCT shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, LCT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
